A Comprehensive Analysis of Prognostic Factors in Head and Neck Squamous Cell Carcinoma: Experience from a Single-center Baş ve Boyun Skuamöz Hücreli Kanserlerinde Prognostik Faktörlerin Kapsamlı Analizi: Tek Merkez Deneyimi
Medical Journal of Bakirkoy, cilt.21, sa.3, ss.246-251, 2025 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 21 Sayı: 3
- Basım Tarihi: 2025
- Doi Numarası: 10.4274/bmj.galenos.2025.2024.11-15
- Dergi Adı: Medical Journal of Bakirkoy
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.246-251
- Anahtar Kelimeler: Head and neck tumors, squamous cell cancer, concurrent chemoradiotherapy, prognostic factors
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: The aim of this study is to evaluate the prognostic factors of adjuvant or definitive radiotherapy (RT) and/or chemoradiotherapy (CRT) in patients with squamous cell head and neck (HN) tumor treated in our clinic. Methods: The prognostic factors in the patients who were treated between February 2017 and May 2021 were retrospectively evaluated. A total of 78 patients diagnosed with HN cancer were included in the study. RT was applied to tumor/tumor lodge ± lymphatics at a dose of 54-70 gray. The prognostic factors, side effects, and overall survival in patients were noted and evaluated. Results: Of a total of 78 patients, 15 (19.2%) were female and 63 (80.8%) were male. The most common tumor location in the patients was larynx (53.8%), followed by oral cavity (24.4%), and oropharynx (15.4%). Twenty-seven (34.6%) patients were in the T2 stage. Additionally, most of the patients were N0 (39 patients, 50%), and 29 (37.2%) patients were N2. Forty-three (55.1%) patients underwent surgery. Forty-three (55.1%) patients received adjuvant RT. Concomitant chemotherapy with RT was administered to 46 (59%) patients. In all groups, significant differences were found in hemoglobin and platelets before and after RT. Borderline significant in white blood cells. N stage of the tumor, smoking habit, and tumor localization were found to be significant for survival. Conclusion: In the treatment of HN cancers, disease-free survival and a functional life in which organs at risk are protected as much as possible are aimed. RT/CRT is a highly toxic, long-term, and organ-preserving therapy. One of the main goals is to provide a survival advantage by increasing local control and protecting patients from side effects.